Kane Biotech Releases Inaugural Business Update Video
September 10 2019 - 4:30PM
Kane Biotech Inc. (TSX-V: KNE), (the “Corporation” or “Kane
Biotech”), a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms, today hosted their
first-ever business update. The video update, included below,
features presentations from several members of Kane’s team.
To view the video, please visit:
https://ir.kanebiotech.com/2019-business-update-video
“I joined Kane Biotech exactly one year ago today, and I am
proud to say that we’ve made notable progress on all of the
initiatives that were laid out when I began.” stated Marc Edwards,
Chief Executive Officer of Kane Biotech. “We have released several
new products and significantly grown our sales in the animal
health/oral care market, and we’ve partnered with a few very
well-known distributors and collaborators in the field in order to
accelerate our growth. We have also furthered the development of
our DispersinB hydrogel for wound care in the human health market
and are now ready to start seeking FDA approval. These
advancements can all be attributed to the world-class team we have
assembled over the past year, many of whom are featured in today’s
update. I believe the combination of this strong team, our unique
product positioned in an emerging market, and our recent funding
from WD Canada have positioned us very well to become the leader in
the biofilm space. We have a number of new milestones on the
horizon, each with the opportunity to be a transformational event
for Kane. I look forward to providing updates on these in the
coming months.”
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms. The Corporation has a
portfolio of biotechnologies, intellectual property (56 patents and
patents pending, trade secrets and trademarks) and products
developed by the Corporation’s own biofilm research expertise and
acquired from leading research institutions. StrixNB(TM),
DispersinB(R), Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM)
and Kane(R) are trademarks of Kane Biotech Inc. The Corporation is
listed on the TSX Venture Exchange under the symbol "KNE".
For more information, please visit
www.kanebiotech.com, or contact:
Marc EdwardsChief Executive OfficerKane Biotech
Inc.
+1
(514) 910-6991
medwards@kanebiotech.com
Ray DupuisChief Financial OfficerKane Biotech Inc.+1 (204)
298-2200
rdupuis@kanebiotech.com
Joe Green US. Investor Relations Edison Inc. +1 (646)
653-7030
jgreen@edisongroup.com
Laine YonkerUS. Investor RelationsEdison Inc. +1 (646) 653
7035
lyonker@edisongroup.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Caution Regarding Forward-Looking
Information
This press release contains certain statements regarding Kane
Biotech Inc. that constitute forward-looking information under
applicable securities law. These statements reflect management’s
current beliefs and are based on information currently available to
management. Certain material factors or assumptions are applied in
making forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
These risks and uncertainties include, but are not limited to,
risks relating to the Company’s: (a) financial condition, including
lack of significant revenues to date and reliance on equity and
other financing; (b) business, including its early stage of
development, government regulation, market acceptance for its
products, rapid technological change and dependence on key
personnel; (c) intellectual property including the ability of the
Company to protect its intellectual property and dependence on its
strategic partners; and (d) capital structure, including its lack
of dividends on its common shares, volatility of the market price
of its common shares and public company costs. Further information
about these and other risks and uncertainties can be found in the
disclosure documents filed by the Company with applicable
securities regulatory authorities, available at www.sedar.com. The
Company cautions that the foregoing list of factors that may affect
future results is not exhaustive.
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Apr 2023 to Apr 2024